540 related articles for article (PubMed ID: 30240471)
1. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
[TBL] [Abstract][Full Text] [Related]
5. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
7. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
8. Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study.
Zhu J; Shi Y; Zhou X; Li Z; Huang X; Han Z; Wang J; Wang R; Ding J; Wu K; Han Y; Fan D
Front Med; 2013 Jun; 7(2):255-63. PubMed ID: 23179137
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
10. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
[TBL] [Abstract][Full Text] [Related]
11. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
13. Decreased infiltration of CD4
Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
[TBL] [Abstract][Full Text] [Related]
14. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
[TBL] [Abstract][Full Text] [Related]
15. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
[TBL] [Abstract][Full Text] [Related]
16. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
[TBL] [Abstract][Full Text] [Related]
17. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid for primary biliary cirrhosis.
Gluud C; Christensen E
Cochrane Database Syst Rev; 2002; (1):CD000551. PubMed ID: 11869580
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
[TBL] [Abstract][Full Text] [Related]
20. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
